OncoMatch/Clinical Trials/NCT05942300
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Is NCT05942300 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CPI-0209 and carboplatin for recurrent ovarian cancer.
Treatment: CPI-0209 · carboplatin — This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy
Must have had at least 1 prior line of platinum-based therapy
Lab requirements
Blood counts
Hemoglobin ≥9 gm/dl, Platelets ≥100,000/μl, ANC ≥1500/μl, INR ≤1.5
Kidney function
Serum creatinine ≤1.5mg/dL or 24-hour clearance ≥50mL/min
Liver function
AST/ALT <2.5x ULN (or <5x ULN if liver metastasis are present); Total bilirubin ≤ ULN or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome
Adequate organ function: Serum creatinine ≤1.5mg/dL or 24-hour clearance ≥50mL/min; AST/ALT <2.5x ULN (or <5x ULN if liver metastasis are present); Total bilirubin ≤ ULN or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome; Hemoglobin ≥9 gm/dl, Platelets ≥100,000/μl ANC ≥1500/μl; INR ≤1.5; Potassium, total calcium (corrected for serum albumin), magnesium, and sodium within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Magee-Womens Research Institute / UPMC Magee Womens Hospital · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify